Cue Biopharma, Merck Extend Biologics Research Alliance

Cue Biopharma, Inc., a biopharma company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells, has extended the term of the research program under its research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease.

Cue Biopharma entered an exclusive license and research collaboration agreement with Merck in November 2017 to develop biologics for the treatment of selected autoimmune diseases. Under the terms of the extension, Cue Biopharma will receive additional financial research support to further study and develop promising preclinical biologics with the objective of identifying clinical candidates.

“We are very pleased with the progress to date in our ongoing strategic collaboration with Merck,” said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. “Extending the research term of our agreement based on promising preclinical data with a goal of identifying a clinical candidate underscores the significant potential of our therapeutic Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform and CUE-300 series in the treatment of debilitating autoimmune disease.”